A phase III study of Calmangafodipir (PledOx®) in patients treated adjuvantly for colorectal cancer
Phase of Trial: Phase III
Latest Information Update: 08 Feb 2018
At a glance
- Drugs Calmangafodipir (Primary)
- Indications Chemotherapy-induced damage
- Focus Registrational; Therapeutic Use
- Acronyms POLAR-A
- Sponsors PledPharma
- 08 Feb 2018 According to a PledPharma media release, the patients enrollment is expected in second half of 2018.
- 16 Nov 2017 According to a PledPharma media release, the company intends to initiate the Phase III study before year end 2017 and to have first patient in by early 2018.
- 03 Nov 2016 New trial record